Compared With DTIs, ctDNA Was Able To Measure Disease Burden More Objectively For Patients With DLBCL, Study Finds

Cancer Network (5/21, Fowler) reported that “compared with diagnosis-to-treatment intervals (DTIs), circulating tumor DNA (ctDNA) was able to measure disease burden more objectively for patients with diffuse large B-cell lymphoma (DLBCL), according to res...